AstraZeneca’s ARIMIDEX® (anastrozole) tablets Direct program provides valuable resources to program enrollees


Michele Meixell

AstraZeneca has been at the forefront of innovation, looking for new avenues for patient support. Two key areas of support include financial assistance and educational resources and materials, which are now available for patients receiving ARIMIDEX® (anastrozole) tablets through ARIMIDEX Direct.

Launched in February 2012, ARIMIDEX Direct is AstraZeneca’s first-ever direct-to-patient program. It enables eligible patients to easily enroll and receive brand-name ARIMIDEX delivered directly to their home for $40 per month, including shipping. Patients who enroll in ARIMIDEX Direct now have access to added support benefits, such as health and wellness tools and education materials, links to an online community, and automatic refills or refill reminders.

Since it was launched, over 2000 patients have enrolled in ARIMIDEX Direct, and the direct-to-patient platform continues to serve as an important way for AstraZeneca to help meet the needs of patients who elect to receive and pay for the brand ARIMIDEX on their own.

See below for more information about ARIMIDEX Direct and visit the website for enrollment information.